CAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care, Inc. today announced that new data from studies evaluating the utility of the Zoom Stroke Solution for the treatment of ischemic stroke will be ...
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ...
"Assessing Safety and Clinical Outcomes of Rinvecalinase Alfa (DM199) in Acute Ischemic Stroke Patients Pre-treated with Intravenous Thrombolytics Only" ...
News-Medical.Net on MSN
Investigational anti-clotting drug reduces risk of second ischemic stroke without bleeding concerns
An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic ...
This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...
DiaMedica Presents the Protocol and Rationale for ReMEDy2, a Pivotal Trial in Patients Suffering Acute Ischemic Stroke Ineligible for tPA and/or Mechanical Thrombectomy ...
"Assessing Safety and Clinical Outcomes of Rinvecalinase Alfa (DM199) in Acute Ischemic Stroke Patients Pre-treated with Intravenous Thrombolytics Only" The poster is P-704. On Thursday May 22, 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results